Phaseline

Companies › Urotronic

Urotronic: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Optilume Urethral DCB
Paclitaxel-coated balloon catheter
TubulinPhase 4Urethral StrictureJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05383274Optilume Urethral DCBPhase 4Urethral StrictureGenitourinaryJun 2027

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Ambrx

Companies built like this

Prokidney YolTech Therapeutics Cisen Pharmaceutical Levee Medical Vensica Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.